Drug Trial Radar · NCT05602792
A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
233
Planned (sponsor's estimate)
Start
Apr 21, 2020
Primary completion
Jul 2023
Study completion Jan 2024
Sponsor
- Lead sponsor
- ImmVira Pharma Co. LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/IIa Study of the Safety and Tolerability of T3011 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors
Conditions
- Advanced Solid Tumor
- Sarcoma
- HNSCC
- Breast Cancer
- Esophagus Cancer
- NSCLC
- Non-melanoma Skin Cancer
Interventions
T3011Biological
T3011 will be administered through intratumoral injection in patients with advanced solid tumors.
T3011Biological
T3011 will be administered through intratumoral injection in patients with sarcoma.
T3011Biological
T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.
T3011Biological
T3011 will be administered through intratumoral injection in patients with breast cancer.
T3011Biological
T3011 will be administered through intratumoral injection in patients with esophagus cancer.
T3011Biological
T3011 will be administered through intratumoral injection in patients with lung cancer.
T3011Biological
T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- In part I and part II, Evaluate the safety and tolerability of escalating doses of single dose and multiple dose IT T3011.Characterize DLTs and identify the MTD of IT T3011.Time frame: Up to 2 years from first dose of T3011
- In part III, Evaluate the safety of multiple dose IT T3011 in the following indications,including sarcoma, Malignant head and neck tumor, breast cancer, esophagus cancer, lung cancer and non-melanoma skin cancer.Time frame: Up to 2 years from first dose of T3011
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China · Recruiting
Beijing Jishuitan Hospital
Beijing, China · Recruiting
Ninth People's Hospital,Shanghai Jiao Tong University School to Medicine
Shanghai, China · Recruiting
Fudan University Cancer Hospital
Shanghai, China · Recruiting
Zhongshan Hospital
Shanghai, China · Recruiting
Shanghai Sixth People's Hospital
Shanghai, China · Not yet recruiting
The Second People's Hospital of Shenzhen
Shenzhen, China · Recruiting
Anhui Provincial Hospital
Hefei, Anhui, China · Recruiting
The Second Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
The Fifth Affiliated Hospital of Sun Yat-sen University
Guanzhou, Guangdong, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Wuhan Union Hospital
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
The First Affiliated Hospital of Zhejiang University Medical College
Hanzhou, Zhejiang, China · Recruiting
Zhejiang Provincial People's Hospital
Hanzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.